Dbv Technologies S.a. - Spons-adr (DBVT)

$0.71

+0.01

(+0.71%)▲

Live

Performance

  • $0.67
    $0.71
    $0.71
    downward going graph

    5.61%

    Downside

    Day's Volatility :5.61%

    Upside

    0.0%

    downward going graph
  • $0.50
    $2.28
    $0.71
    downward going graph

    29.24%

    Downside

    52 Weeks Volatility :77.96%

    Upside

    68.86%

    downward going graph

Returns

PeriodDbv Technologies S.a. - Spons-adr Sector (Health Care)Index (Russel 2000)
3 Months
-23.69%
3.6%
0.0%
6 Months
-46.66%
10.2%
0.0%
1 Year
-67.05%
19.6%
0.0%
3 Years
-93.68%
16.8%
-23.0%

Highlights

Market Capitalization
76.2M
Book Value
$0.82
Earnings Per Share (EPS)
-0.91
PEG Ratio
0.0
Wall Street Target Price
5.33
Profit Margin
0.0%
Operating Margin TTM
-2914.9%
Return On Assets TTM
-34.89%
Return On Equity TTM
-72.64%
Revenue TTM
13.8M
Revenue Per Share TTM
0.14
Quarterly Revenue Growth YOY
-49.3%
Gross Profit TTM
4.8M
EBITDA
-79.7M
Diluted Eps TTM
-0.91
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.19
EPS Estimate Next Year
-0.84
EPS Estimate Current Quarter
-0.45
EPS Estimate Next Quarter
-0.47

Analyst Recommendation

Buy
    75%Buy
    12%Hold
    12%Sell
Based on 8 Wall street analysts offering stock ratings for Dbv Technologies S.a. - Spons-adr (by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
7
Hold
1
1
1
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 650.7%

Current $0.71
Target $5.33

Technicals Summary

Sell

Neutral

Buy

Dbv Technologies S.a. - Spons-adr is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Dbv Technologies S.a. - Spons-adr
Dbv Technologies S.a. - Spons-adr
0.71%
-46.66%
-67.05%
-93.68%
-95.27%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Dbv Technologies S.a. - Spons-adr
Dbv Technologies S.a. - Spons-adr
NA
NA
0.0
-1.19
-0.73
-0.35
NA
0.82
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Dbv Technologies S.a. - Spons-adr
Dbv Technologies S.a. - Spons-adr
Buy
$76.2M
-95.27%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Dbv Technologies S.a. - Spons-adr

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 8.87M → 1.16M (in $), with an average decrease of 50.8% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -11.18M → -33.11M (in $), with an average decrease of 82.8% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 149.6%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 138.5%

Institutional Holdings

  • Baker Bros Advisors LP

    7.59%

  • Yiheng Capital LLC

    3.28%

  • BRAIDWELL LP

    2.54%

  • Point72 Asset Management, L.P.

    1.62%

  • Vivo Capital, LLC

    1.41%

  • Morgan Stanley - Brokerage Accounts

    0.33%

Company Information

dbv technologies is opening up a decisive new approach to the treatment of allergy – a major public health issue that is constantly increasing in prevalence. food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need. dbv technologies (incorporated in 2002) has developed a unique, proprietary, worldwide-patented technology for administering an allergen to intact skin and avoiding massive transfer to the blood. the viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient's tolerability of peanut and thus considerably lower the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen. the product's clinically proven safety of use enables the application of effective desensitization techniques (the efficacy of which is acknowledged worldwide) in the most severe forms of the allergy. dbv technologies is focusing on food allergies (milk and

Organization
Dbv Technologies S.a. - Spons-adr
Employees
106
CEO
Mr. Daniel Tassé
Industry
Health Technology

Discover More

FAQs